Roche: Alnylam presents positive results from the KARDIA-1 Phase 2 dose-ranging study of zilebesiran, an investigational RNAi therapeutic in development for the treatment of hypertension in patients at high cardiovascular risk Samstag, 11. November 2023 - 22:28

Investor Update

Alnylam presents positive results from the KARDIA-1 Phase 2 dose-ranging study of zilebesiran, an investigational RNAi therapeutic in development for the treatment of hypertension in patients at high cardiovascular risk

Dear Investor,

Please find attached a press release by Alnylam:

http://roche.com/231111_Alnylam_Kardia_1_Phase

Do not hesitate to contact us for any further questions.

With best regards,

Roche Investor Relations
Dr. Bruno Eschli Phone: +41 61 68-75284 e-mail: bruno.eschli@roche.com	Dr. Sabine Borngräber Phone: +41 61 68-88027 e-mail: sabine.borngraeber@roche.com
Dr. Birgit Masjost Phone: +41 61 68-84814 e-mail: birgit.masjost@roche.com	Dr. Gerard Tobin Phone: +41 61 68-72942 e-mail: gerard.tobin@roche.com

Investor Relations North America
Loren Kalm Phone: +1 650 225 3217 e-mail: kalm.loren@gene.com